These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 19034031

  • 1. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.
    Norgard NB, Saya S, Hann CL, Hennebry TA, Schechter E, Dale GL.
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):536-9. PubMed ID: 19034031
    [Abstract] [Full Text] [Related]

  • 2. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V.
    Thromb Res; 2007 Dec; 119(3):277-84. PubMed ID: 16563469
    [Abstract] [Full Text] [Related]

  • 3. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R.
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [Abstract] [Full Text] [Related]

  • 4. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [Abstract] [Full Text] [Related]

  • 5. Cangrelor attenuates coated-platelet formation.
    Norgard NB, Hann CL, Dale GL.
    Clin Appl Thromb Hemost; 2009 Mar; 15(2):177-82. PubMed ID: 18796456
    [Abstract] [Full Text] [Related]

  • 6. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H, Lask S, Engelhardt A, Mügge A.
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [Abstract] [Full Text] [Related]

  • 7. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ, Tóth-Zsámboki E, Vargová K, László A, Masszi T, Kerecsen G, Préda I, Kiss RG.
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [Abstract] [Full Text] [Related]

  • 8. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [Abstract] [Full Text] [Related]

  • 9. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
    Saraf S, Wellsted D, Sharma S, Gorog DA.
    Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
    [Abstract] [Full Text] [Related]

  • 10. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S, Della Pina F, Rizza A, Buffa M, De Filippis R, Gianetti J, Clerico A.
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [Abstract] [Full Text] [Related]

  • 11. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
    Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL.
    J Thromb Haemost; 2007 Jan; 5(1):75-81. PubMed ID: 17002661
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
    Storey RF, Wilcox RG, Heptinstall S.
    Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
    [Abstract] [Full Text] [Related]

  • 13. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
    [Abstract] [Full Text] [Related]

  • 14. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
    Tanaka KA, Szlam F, Kelly AB, Vega JD, Levy JH.
    Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
    [Abstract] [Full Text] [Related]

  • 15. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
    Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL.
    Arch Cardiovasc Dis; 2010 Jan; 103(1):39-45. PubMed ID: 20142119
    [Abstract] [Full Text] [Related]

  • 16. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ.
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [Abstract] [Full Text] [Related]

  • 17. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
    Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S.
    J Thromb Haemost; 2008 Jul; 6(7):1153-9. PubMed ID: 18485086
    [Abstract] [Full Text] [Related]

  • 18. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC, Crain EJ, Watson CA, Jiang X, Hua J, Bostwick JS, Ogletree ML, Schumacher WA, Rehfuss R.
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [Abstract] [Full Text] [Related]

  • 19. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.
    Angiolillo DJ, Capranzano P, Desai B, Shoemaker SB, Charlton R, Zenni MM, Guzman LA, Bass TA.
    Thromb Res; 2009 Jul; 124(3):318-22. PubMed ID: 19012950
    [Abstract] [Full Text] [Related]

  • 20. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
    Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C.
    J Thromb Haemost; 2005 Jan; 3(1):85-92. PubMed ID: 15634270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.